LC-MS/MS法测定人血浆中辛伐他汀浓度

为了建立高效液相色谱-质谱联用法测定人血浆中辛伐他汀浓度的方法,选用Ultimate XB-C₁₈柱（2.1 m×100 mm,3 μm）,以V（甲醇）：V（乙腈）∶V（2.5 mmol/L乙酸铵）=45∶50∶5的溶液为流动相,样品用沉淀蛋白法处理后进样,流速为0.3 mL/min。选用Finnigan TSQ Quantum Access液质联用（LC-MS/MS）分析仪的选择反应监测（SRM）扫描方式进行监测,选择电喷雾离子源ESI,正离子方式。辛伐他汀的线性范围为0.1～20 μg/L,定量下线为0.1 μg/L。准确度与精密度结果显示,方法日间、日内相对标准偏差（RSD）小于15%,方法提取回收率为71.96%～78.44%。稳定性试验中,血浆中辛伐他汀在各种储存条件下均较稳定。试验表明,该方法快速、灵敏,专属性强、重现性好,可用于人血浆中辛伐他汀浓度的测定和药代动力学研究。     

LC-MS/MS法测定比格犬血浆中氢吗啡酮

氢吗啡酮(Hydromorphone,HYD)为半合成的强镇痛药,其结构与吗啡类似,而镇痛作用大约是吗啡的8倍,且副作用较吗啡轻,临床主要用于缓解癌症、术后、软组织创伤等引起的中强度疼痛.HYD在体内发生广泛的结合代谢,HYD-3-葡萄糖苷酸是其主要代谢物.HYD的消除半衰期仅为2.5 h,为获得良好镇痛效果,HYD在临床用药时需每隔4小时给药一次[1],为方便患者用药,延长给药间隔的缓释制剂的研制引起国内外学者的关注,本实验旨在建立一种快速、灵敏的液相色谱-质谱联用法测定比格犬给予HYD缓释制剂后血浆中HYD的浓度,以评价其缓释特征.     

LC-MS/MS法测定人血浆中氨氯地平的浓度

为了快速、准确地检测人血浆中氨氯地平的浓度,建立了高效液相色谱-质谱联用检测方法。选用Eclipse XDB-C₁₈色谱柱,以甲醇-1 mM乙酸铵溶液-0.1%甲酸溶液为流动相,采用梯度洗脱方法进行分离,样品经乙腈沉淀后进样,选用3200Q-trap型质谱仪的多重反应监测（MRM）扫描方式进行检测。氨氯地平线性范围为0.100~20.000 μg/L,定量下限为0.100 μg/L 。准确度与精密度结果显示：方法日间、日内变异均小于15%,相对偏差为-3.85%~1.94%,低、中、高3个浓度提取回收率为94.90%~97.84%,稳定性好。该方法专属性强、样品处理简便、灵敏度高,可用于人体氨氯地平血药浓度的测定及其制剂的人体药代动力学研究。     

LC-MS/MS法测定比格犬血浆中丁酸氯维地平浓度

本研究建立了液相色谱-串联质谱（LC-MS/MS）法测定比格犬血浆中丁酸氯维地平浓度,用来研究自制的丁酸氯地平脂肪乳注射液与原研产品在比格犬体内的药代动力学参数,同时比较其生物等效性。实验以氨氯地平为内标,选取Phenomenex Luna C8色谱柱（2.0 mm×150 mm×5 μm）,以甲醇0.1%甲酸溶液（82∶18,V/V）为流动相,采用Waters Quattro Micro API的正离子检测方式,用MassLynx4.1软件进行数据处理。结果表明,丁酸氯维地平标准曲线的线性范围为0.4～100 μg/L。主要的药代动力学参数：参比制剂和试验制剂的C_max平均值分别为（58.748±16.738）μg/L和（53.706±18.963）μg/L;T_max分别为（2.938±0.678）μg/L和（2.875±0.991）μg/L;T_1/2分别为（11.88±3.824）min和（11.587±3.634）min;AUC_0→t分别为（1 883.821±647.882）μg•min/L和(1 856.541±590.653) μg•min/L;AUC_0→∞分别为(1 889.834±649.135) μg•min/L和(1 863.485±592.039) μg•min/L。方差分析表明,这两种制剂的主要药动学参数之间无明显差异;双单侧t检验结果表明,两制剂在比格犬体内为生物等效制剂。     

LC-MS/MS法测定比格犬血浆中氯吡格雷活性代谢物

建立了一种定量测定比格犬血浆中氯吡格雷活性代谢物（active metabolize, AM）的液相色谱-串联质谱（LC-MS/MS）法。采血管中加入酯酶抑制剂敌敌畏,采样后立即离心处理,取上层血浆,加入2-溴-3’-甲氧基苯乙酮（MPB）进行衍生化,反应完成后直接加入含0.1%甲酸的冰乙腈沉淀蛋白,取上清液,测定氯吡格雷活性代谢物的衍生化产物（MP-AM）。以乙腈0.1%甲酸为流动相,梯度洗脱,API4000电喷雾离子源,多反应监测（MRM）模式扫描。在优化的实验条件下,获得了峰宽较窄且对称的色谱峰;MP-AM的线性范围为1~1 000 μg/L,相关系数大于0.995;生物基质效应较小,提取回收率在92.8%~95.1%之间,相对标准偏差小于8.27%。该方法的准确度和精密度均符合国家食品药品监督管理总局（China Food and Drug Administration, CFDA）的相关要求,适用于比格犬血浆中氯吡格雷的药代动力学研究。     

LC-MS/MS分析血浆中脂肪酸及代谢产物

建立了高效液相色谱-串联质谱（LC-MS/MS）同时测定血浆中脂肪酸花生四烯酸（AA）及其代谢产物13-羟基十八碳烯酸（13-HODE）和9-羟基十八碳烯酸（9-HODE）的方法。采用Strata-X固相萃取柱净化,BEH C18色谱柱分离,以乙腈 水为流动相,流速0.2 mL/min,等度洗脱;电喷雾离子源负离子模式和多反应监测模式定量。结果表明,3种物质在0.5~50 μg/L范围内线性关系良好,相关系数为0.994 2~0.996 0;低、中、高3个加标水平的平均回收率为97.42%~101.46%;日内相对标准偏差为2.72%~6.11%,日间相对标准偏差为3.87%~6.39%;AA、13-HODE和9-HODE定量限分别为0.5、0.5、1.0 μg/L。该方法简单、灵敏、快速、可靠,可用于血浆中脂肪酸及其代谢产物的检测分析。     

LC-MS/MS定量分析血浆中消旋卡多曲代谢物

Orally administered racedotril is rapidly hydrolysed to the more potent enkephalinase inhibitor thiorphan in vivo. A sensitive and specific liquid chromatography-tandem mass spectrometry method was developed and validated to quantify thiorphan in human plasma using lisinopril as the internal standard. After a simple protein precipitation with methanol, the post-treatment samples were analyzed on a CN column interfaced with a tripe-quadrupole tandem mass spectrometer using negative electrospray ionization. The method was validated to demonstrate the specificity, lower limit of quantification, accuracy, and precision of measurements. The assay was linear over the concentration range 9.38～600 ng/mL using a 5 μL aliquot of plasma. The correlation coefficients for the calibration curves ranged from 0.998 5 to 0.999 5. The intra-and inter-day precisions over the entire concentration were not more than 6.33%. Methanol and water (35∶65, v/v)is used as the isocratic mobile phase, with 0.1% of formic acid in water. The method was successfully applied for pharmacokinetic study after a single oral administration of 200 mg racecadotril to 20 healthy volunteers.     

LC-MS/MS法测定犬血浆中脂质纳米粒10-羟基喜树碱浓度

10-hydroxycamptothecin,camptothecin analogue,is an antitumor agent that targets the nuclear enzyme topoisomerase I. 10-hydroxycamptothecin is injected by sodium salt form in clinic, and myelosuppression is the major toxicity. To enhance water solubility and reduce the toxicity, lipid nanoparticle which is water-soluble was designed. The quantitative analyses of liposomal and total 10-hydroxycamptothecin in dog plasma were developed and validated by liquid chromatographic-tandem mass spectrometry(LC-MS/MS). Two preparation procedures were developed to separate liposomal 10-hydroxycamptothecin, one was solid phase extraction, the other was liquid-liquid extraction. The analyte and internal standand(camptothecin) were separated on a Zorbax SB-C₁₈ column using the mobile phase consisting of V(acetonitrile):V(water):V(formic acid)＝70:30:0.2. Electropray ionization source of MS was applied and operated in positive ion mode. The peak area of the m/z 365→321 transition of 10-hydroxycamptothecin and that of m/z 349→305 transition of the IS were measured. The linear calibration curve for liposmal 10-hydroxycamptothecin is obtained in the concentration range of 1.00- 1 000μg L^－1, and that for total 10-hydroxycamptothecin is obtained in the concentration range of 1.00- 2 000μg L－1. The recoveries of solid phase extraction and liquid-liquid extraction methods are 48.1%-52.4% and 79.6%-83.0%, respectively. This validated LC-MS/MS assay is successfully applied to pharmacokinetic study of 10-hydroxycamptothecin loaded lipid nanoparticle in dogs after administration single dosages of 0.5, 1, 2 mg kg^－1 and multiple dosage of 1.0 mg kg^－1 d^－1 10-hydroxycamptothecin lipid nanoparticle.     

LC-MS/MS法定量测定人血浆中CPRC-127血药浓度

A sensitive liquid chromatography-electrospray ionization-tandem mass spectrometric(LC-MS/MS) method for the determination of CPRC-127 in human plasma was developed and validated. The plasma was extracted using a liquid-liquid phase extraction(LLE), and the sample extract was injected onto the LC-MS/MS system. The limit of quantitation(LLOQ) for CPRC-127 is 0.5 μg•L^－1. This method allows the reproducible and accurate quantification with the concentration range of 0.5-1 000 μg•L^－1. This method can be applied to the quantitation of CPRC-127 in human plasma.     

LC-MS/MS���ⶨ��Ѫ�����׸�����Ũ��

??????Ч??????????????÷????????????????????????Kromasil-C₁₈ ???????50mm??4.6mm??5??m??????V(????):V(0.1%????)=75??25??1mmol•L^-1??????????????????????????з???????ó???????????????????3200QTrap?????????????????????????????MRM????跽????м????????ε??????Χ?3.0~3000.0??g•L^-1???????????3.0??g•L^-1?????????????????????????????????С??15%????????-1.40%~2.07%??????????????????98.2??7.6??%????????á??÷????????????????????????????????????????????????????????????????????о???     

液相色谱-串联质谱法测定人血浆中克林霉素

建立了测定人血浆中克林霉素的LC-MS/MS法。血浆样本用乙腈沉淀蛋白后,选用Shim-pack VP-ODS色谱柱（150 mm ×2.0 mm×5 μm）,以 V(甲醇)∶V(10 mmol•L^-1乙酸铵（含0.25%甲酸）)=55∶45为流动相,流速为0.4 mL•min^-1。选用API3200型三重四极杆串联质谱仪的多重反应监测（MRM）扫描方式进行监测,电喷雾离子化源,正离子方式,选择监测离子反应分别为 m/z 425.2→126.3（克林霉素）和 m/z 256.2→167.3（内标苯海拉明）。克林霉素和苯海拉明的保留时间分别为1.77 min和1.79 min;血浆中克林霉素的线性范围为0.030 0~10.0 mg•L^-1（r>0.99）,定量下限为0.030 0 mg•L^-1;日内、日间相对标准差（RSD）均小于6%;相对偏差（RE）均在±6%的范围以内;平均提取回收率为（101.1± 2.6）%;稳定性试验中,血浆中克林霉素在各种贮存条件下均较稳定。该方法快速、灵敏、专属性强、重现性好,适用于人体内克林霉素的药代动力学研究。     

LC/MS和LC-MS/MS定性检测保健品中非法添加的伐地那非

采用LC/MS和LC-MS/MS法同时检测保健品中非法添加的伐地那非。用乙酸乙酯提取,以10 mmol•L^-1的甲酸铵（pH 3.5）和乙腈为流动相,分别用Agilent Zorbax SB C₁₈（150 mm×2.1 mm×5 μm）和Agilent Zorbax SB C₁₈（100 mm×2.1 mm×3.5 μm）色谱柱分离,采用电喷雾离子源,正离子扫描方式进行分析检测。该方法简便、快捷、可靠,适用于保健品中非法添加伐地那非的常规检测。     

高效液相色谱-串联质谱法测定人血浆中8601、8602、8603的含量

A sensitive liquid chromatography-electrospray ionization-tandem mass spectrometric(LC-MS/MS) method for determination of compound 8601, 8602, 8603 in plasma was developed. The plasma compound 8601, 8602, 8603 was extracted using a solid phase extraction(SPE), and the sample extract was injected onto the LC-MS/MS system. The limit of quantitation(LLOQ) for compound 8601, 8602, 8603 is 0.500 μg•L^－1. This method can be applied to the quantitation compound 8601, 8602, 8603 in plasma.     

LC-MS/MS法定性检测保健品中非法添加的镇静催眠药

建立了同时检测保健品中非法添加的8种镇静催眠药的分析方法。用甲醇直接提取,以10 mmol•L^-1 甲酸铵（pH 3.5）和乙腈为流动相,采用Agilent Zorbax SB C₁₈（100 mm × 2.1 mm×3.5 μm）色谱柱进行分离,电喷雾离子源,正离子多反应监测扫描方式分析检测。8种镇静催眠药的检测限均不高于1 mg•kg^-1,回收率为73.3%~99.0%。